(MedPage Today) — The novel opioid agonist/antagonist nalbuphine offered relief from chronic cough associated with idiopathic pulmonary fibrosis (IPF), the phase IIb CORAL trial showed.
Nalbuphine extended release (ER) reduced objective cough…
Source link : https://www.medpagetoday.com/pulmonology/generalpulmonary/119552
Author :
Publish date : 2026-01-23 15:24:00
Copyright for syndicated content belongs to the linked Source.
